眾業達(002441.SZ):擬向銀行申請的綜合授信額度(含貸款)增至不超20億元
格隆匯 11 月 27日丨眾業達(002441.SZ)公佈,公司第五屆董事會第五次會議決議,審議通過《關於增加向銀行申請綜合授信額度的議案》;
經公司第四屆董事會第二十八次會議審議通過,同意公司從2019年5月29日至2022年5月28日向銀行申請貸款累計餘額不超過8億元。現因公司業務發展需要,同意公司向銀行申請的綜合授信額度(含貸款)增加至不超過20億元,有效期為本次董事會審議通過之日起3年。以上授信額度(含貸款)不等於公司的實際融資金額,實際融資金額應在授信額度內以公司與銀行實際發生的融資金額為準。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.